BriaCell Anti-Cancer Technology Published in Leading Cancer Drug Discovery Journal
June 24 2022 - 9:00AM
BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX:
BCT) (“BriaCell” or the “Company”), a clinical-stage
biotechnology company specializing in targeted immunotherapies for
cancer, is pleased to announce the publication of novel scientific
data and clinical data (previously reported) on BriaCell’s lead
candidate, Bria-IMT™. The abstract of the paper was published
on-line in Recent Patents on Anti-Cancer Drug Discovery, a
publication focused on research (where patents have been
registered) in leading therapeutic areas, targets, and agents
related to anti-cancer drug discovery. The publication highlights
BriaCell’s approach to developing novel cellular immunotherapies
for cancer and the safety and efficacy of Bria-IMT™ against
advanced breast cancer in a prior clinical study through a
potentially unique mechanism of action. The full text of the
article will be made available.
“We are thrilled to see the congruence of our
scientific insights and the clinical activity of our immunotherapy
in advanced breast cancer patients,” stated Dr. Williams,
BriaCell’s President & CEO. “This paper highlights our findings
of rapid tumor shrinkage in multiple anatomic locations including
difficult to treat sites like the brain. We are even more excited
to see the potential positive effect on survival in these patients.
Having these scientific and clinical findings published in such a
highly regarded journal is a significant achievement for BriaCell.
The results support our approach for selecting patients most likely
to benefit from our immunotherapy. This undergirds our current
strategy of building a pipeline of off-the-shelf personalized
immunotherapies as potentially safe and effective treatments for
advanced breast cancer and other cancers,” Dr. Williams added.
As previously reported, clinical data in 4
advanced breast cancer patients who had failed multiple prior
treatments showed that the Bria-IMT™ (also known as SV-BR-1-GM)
immunotherapy regimen was safe and well tolerated and produced
immune responses in all 4 patients. Importantly, the overall
survival was over 33 months for three of the four patients
suggesting an overall survival benefit. Rapidly disappearing tumors
in the lung, the breast and the soft tissues of one patient
re-appeared after treatment was ceased; then the tumors rapidly
shrunk again upon re-treatment with the Bria-IMT™ regimen. Complete
regression of brain metastases was observed in the patient who
matched Bria-IMT™ at two HLA types suggesting a unique mechanism of
action for Bria-IMT™.
The details of the publication are the
following:
Journal: Recent Patents on
Anti-Cancer Drug Discovery
Title: Regression of Breast
Cancer Metastases Following Treatment with Irradiated SV-BR-1-GM, a
GM-CSF Overexpressing Breast Cancer Cell Line: Intellectual
Property and Immune Markers of Response
The abstract of the publication can be accessed
via the following link:
https://briacell.com/scientific-publications/.
BriaCell is currently conducting a Phase I/IIa
study of Bria-IMT™ in advanced breast cancer (listed in
ClinicalTrials.gov as NCT03328026). Additionally, the Company is
developing novel targeted off-the-shelf personalized
immunotherapies, also known as Bria-OTS™, for advanced breast
cancer and other cancers.
About BriaCell Therapeutics
Corp.
BriaCell is an immuno-oncology focused
biotechnology company developing targeted and effective approaches
for the management of cancer. More information is available at
https://briacell.com/.
Safe Harbor
This press release contains “forward-looking
statements” that are subject to substantial risks and
uncertainties. All statements, other than statements of historical
fact, contained in this press release are forward-looking
statements. Forward-looking statements contained in this press
release may be identified by the use of words such as “anticipate,”
“believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,”
“seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,”
“target,” “aim,” “should,” “will,” “would,” or the negative of
these words or other similar expressions, although not all
forward-looking statements contain these words. Examples of
forward-looking statements in this news release include, among
others, statements the Company makes regarding: (i) the results,
safety and efficacy of any potential treatment regime with
Bria-IMT™ treatments; (ii) the potential impact of obtaining Fast
Track status with the FDA; (iii) which patients the Fast Track
designation may apply to; (iv) the nature and frequency of
communications with the FDA; and (v) any acceleration in the drug
approval and access process for Bria-IMT™. Forward-looking
statements are based on BriaCell’s current expectations and are
subject to inherent uncertainties, risks and assumptions that are
difficult to predict. Further, certain forward-looking statements
are based on assumptions as to future events that may not prove to
be accurate. These and other risks and uncertainties are described
more fully under the heading “Risks and Uncertainties” in the
Company's most recent Management’s Discussion and Analysis, under
the heading "Risk Factors" in the Company's most recent Annual
Information Form, and under “Risks and Uncertainties” in the
Company's other filings with the Canadian securities regulatory
authorities and the U.S. Securities and Exchange Commission, all of
which are available under our profiles on SEDAR at www.sedar.com
and on EDGAR at www.sec.gov. Forward-looking
statements contained in this announcement are made as of this date,
and BriaCell Therapeutics Corp. undertakes no duty to update such
information except as required under applicable law.
Neither Toronto Stock Exchange nor its
Regulation Services Provider (as that term is defined in the
policies of the Toronto Stock Exchange) accepts responsibility for
the adequacy or accuracy of this release.
Contact Information
Company Contact:William V.
Williams, MDPresident &
CEO1-888-485-6340info@briacell.com
Media Relations:Jules
AbrahamDirector of Public RelationsCORE
IR917-885-7378julesa@coreir.com
Investor Relations Contact:CORE
IRinvestors@briacell.com
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
BriaCell Therapeutics (NASDAQ:BCTX)
Historical Stock Chart
From Sep 2023 to Sep 2024